Human Facilitating Cells Enhance Stem Cell Engraftment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic protocols for hematopoietic stem cell transplantation face challenges in achieving long-term engraftment and inducing donor-specific tolerance, often requiring extensive immunosuppression and risking graft-versus-host disease.
Innovation Solution
The use of human facilitating cells (hFCs) with specific phenotypic markers, such as CD8+/TCR-/CD56 dim/neg, combined with human hematopoietic stem cells (HSCs), enhances engraftment and tolerance by improving the colony-forming ability of HSCs and reducing the need for intense immunosuppression, allowing for the establishment of a chimeric immune system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If extensive immunosuppression is used to achieve long-term engraftment, then engraftment success is improved, but risk of graft-versus-host disease and toxicity increases
Solution Approach 1:
The patent introduces facilitating cells as an intermediary component that mediates between the transplanted stem cells and the recipient's immune system. These facilitating cells express specific surface markers (CD34+, CD38-, CD45RA+) that enable them to interact with host immune cells, promoting tolerance induction without requiring extensive immunosuppression. The facilitating cells act as a bridge that facilitates engraftment while reducing graft-versus-host disease risk.
Solution Approach 2:
The patent changes the immunological parameters by selecting and transplanting a specific cell population with defined phenotypic characteristics (CD34+, CD38-, CD45RA+). This parameter-based selection identifies cells that are less immunogenic and more capable of inducing tolerance, thereby reducing the need for intensive immunosuppressive therapy while maintaining engraftment success.
2Duration of action of stationary object
If intense immunosuppression is applied to ensure engraftment, then engraftment durability is improved, but patient toxicity increases
Solution Approach 1:
The facilitating cells serve as intermediaries that promote durable engraftment through biological mechanisms rather than pharmacological immunosuppression. They interact with host dendritic cells and T cells to induce regulatory responses, providing long-term engraftment durability without the toxic side effects of intensive immunosuppressive drugs.
Solution Approach 2:
The transplanted cell population possesses inherent properties that enable self-protection and self-regulation. The CD34+, CD38-, CD45RA+ phenotype confers resistance to immune rejection and the ability to self-regulate the immune response, reducing the need for external immunosuppressive intervention and its associated toxicity.
3Ease of manufacture
If conventional stem cell transplantation is performed without facilitating cells, then treatment simplicity is maintained, but long-term engraftment is insufficient
Solution Approach 1:
The patent segments the transplanted cell population into two functional components: stem cells (providing repopulation capacity) and facilitating cells (providing engraftment support). This segmentation allows each component to perform its specialized function, with the facilitating cells specifically enhancing engraftment while the stem cells provide long-term hematopoietic regeneration, thereby improving overall engraftment reliability.
Solution Approach 2:
The patent creates a composite cell product combining stem cells and facilitating cells with complementary phenotypic characteristics. This composite population leverages the repopulation capacity of stem cells and the engraftment-promoting properties of facilitating cells, achieving superior long-term engraftment outcomes compared to stem cell transplantation alone.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to human facilitating cells (hFC), and methods of isolating, characterizing, and using such hFCs.